Carcinoma, Hepatocellular
"Carcinoma, Hepatocellular" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
Descriptor ID |
D006528
|
MeSH Number(s) |
C04.557.470.200.025.255 C04.588.274.623.160 C06.301.623.160 C06.552.697.160
|
Concept/Terms |
Carcinoma, Hepatocellular- Carcinoma, Hepatocellular
- Carcinomas, Hepatocellular
- Hepatocellular Carcinomas
- Liver Cell Carcinoma, Adult
- Liver Cancer, Adult
- Adult Liver Cancer
- Adult Liver Cancers
- Cancer, Adult Liver
- Cancers, Adult Liver
- Liver Cancers, Adult
- Liver Cell Carcinoma
- Carcinoma, Liver Cell
- Carcinomas, Liver Cell
- Cell Carcinoma, Liver
- Cell Carcinomas, Liver
- Liver Cell Carcinomas
- Hepatocellular Carcinoma
- Hepatoma
- Hepatomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Hepatocellular".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Hepatocellular".
This graph shows the total number of publications written about "Carcinoma, Hepatocellular" by people in UAMS Profiles by year, and whether "Carcinoma, Hepatocellular" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2024 | 4 | 0 | 4 | 2023 | 9 | 0 | 9 | 2022 | 12 | 0 | 12 | 2021 | 14 | 0 | 14 | 2020 | 12 | 1 | 13 | 2019 | 4 | 2 | 6 | 2018 | 6 | 1 | 7 | 2017 | 6 | 0 | 6 | 2016 | 6 | 3 | 9 | 2015 | 1 | 0 | 1 | 2014 | 6 | 0 | 6 | 2013 | 5 | 2 | 7 | 2012 | 2 | 1 | 3 | 2011 | 5 | 0 | 5 | 2010 | 5 | 2 | 7 | 2009 | 5 | 1 | 6 | 2008 | 5 | 1 | 6 | 2007 | 2 | 1 | 3 | 2006 | 2 | 0 | 2 | 2005 | 2 | 2 | 4 | 2004 | 2 | 1 | 3 | 2003 | 6 | 1 | 7 | 2002 | 2 | 1 | 3 | 1999 | 0 | 2 | 2 | 1997 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Hepatocellular" by people in Profiles over the past ten years.
-
Pham YT, Jin A, Wang R, Behari J, Koh WP, Yuan JM, Luu HN. Low-Carbohydrate Diet Score and Risk of Hepatocellular Carcinoma: Findings from a Prospective Cohort Study. Cancer Prev Res (Phila). 2024 Jun 04; 17(6):265-274.
-
Leung YK, Lee SG, Wang J, Guruvaiah P, Rusch NJ, Ho SM, Park C, Kim K. The Loss of an Orphan Nuclear Receptor NR2E3 Augments Wnt/?-catenin Signaling via Epigenetic Dysregulation that Enhances Sp1-? catenin-p300 Interactions in Hepatocellular Carcinoma. Adv Sci (Weinh). 2024 Aug; 11(29):e2308539.
-
Beltr?n Ponce S, Gokun Y, Douglass F, Dawson L, Miller E, Thomas CR, Pitter K, Conteh L, Diaz DA. Disparities in outcomes and access to therapy options in hepatocellular carcinoma. J Natl Cancer Inst. 2024 Feb 08; 116(2):264-274.
-
Willett RA, Tryndyak VP, Beland FA, Pogribny IP. Cellular and molecular alterations in a human hepatocellular in vitro model of nonalcoholic fatty liver disease development and stratification. J Environ Sci Health C Toxicol Carcinog. 2024; 42(1):74-92.
-
Thandassery RB, Lavender CA, Perisetti A, Beheshti M. Improving prognostication in patients with hepatocellular carcinoma undergoing loco-regional therapy using pre- and post-locoregional therapy scores. Abdom Radiol (NY). 2024 02; 49(2):631-641.
-
Wang M, Shui AM, Ruck J, King E, Rahimi R, Kappus M, Volk ML, Ganger DR, Ladner DP, Duarte-Rojo A, Huang CY, Verna EC, Lai JC. The liver frailty index is a predictor of healthcare utilization after liver transplantation in older adults. Clin Transplant. 2024 01; 38(1):e15219.
-
Claasen MPAW, Sneiders D, Rakk? YS, Adam R, Bhoori S, Cillo U, Fondevila C, Reig M, Sapisochin G, Tabrizian P, Toso C. European Society of Organ Transplantation (ESOT) Consensus Report on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma. Transpl Int. 2023; 36:11648.
-
Todorova VK, Byrum SD, Mackintosh SG, Jamshidi-Parsian A, Gies AJ, Washam CL, Jenkins SV, Spiva T, Bowman E, Reyna NS, Griffin RJ, Makhoul I. Exosomal MicroRNA and Protein Profiles of Hepatitis B Virus-Related Hepatocellular Carcinoma Cells. Int J Mol Sci. 2023 Aug 23; 24(17).
-
Behari J, Gougol A, Wang R, Luu HN, Paragomi P, Yu YC, Molinari M, Chopra K, Malik SM, Geller D, Yuan JM. Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis. Hepatol Commun. 2023 07 01; 7(7).
-
Bailey RE, Pugliesi RA, Borja-Cacho D, Borhani AA. Imaging Evaluation of the Living Liver Donor: A Systems-Based Approach. Radiol Clin North Am. 2023 Sep; 61(5):771-784.
-
Zongo SV, Djigma FW, Yonli AT, Sorgho PA, Nagalo BM, Traore L, Somda D, Amegnona LJ, Languie E, Some CCB, Sia LMJ, Sourabie IB, Sombie RA, Serme AK, Obiri-Yeboah D, Simpore J. Association of DRB1*11 and DRB1*12 alleles of the HLA system with the evolution of the Hepatitis B virus infection in Burkina Faso. Mol Biol Rep. 2023 Jun; 50(6):5039-5047.
-
Yu YC, Paragomi P, Wang R, Liang F, Luu HN, Behari J, Yuan JM. High serum magnesium is associated with lower risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease. Cancer. 2023 08 01; 129(15):2341-2347.
-
Thomas CE, Adibi JJ, Kuipers AL, Diergaarde B, Luu HN, Jin A, Koh WP, Gao YT, Adams-Haduch J, Wang R, Lokshin A, Behari J, Yuan JM. Soluble CD137 and risk of hepatocellular carcinoma: nested case-control studies in cohorts in Shanghai and Singapore. Br J Cancer. 2023 06; 128(11):2081-2088.
-
Moawad AW, Morshid A, Khalaf AM, Elmohr MM, Hazle JD, Fuentes D, Badawy M, Kaseb AO, Hassan M, Mahvash A, Szklaruk J, Qayyum A, Abusaif A, Bennett WC, Nolan TS, Camp B, Elsayes KM. Multimodality annotated hepatocellular carcinoma data set including pre-?and post-TACE with imaging segmentation. Sci Data. 2023 01 18; 10(1):33.
-
Abdelsattar S, Sweed D, Kamel HFM, Kasemy ZA, Gameel AM, Elzohry H, Ameen O, Elgizawy EI, Sallam A, Mosbeh A, Abdallah MS, Khalil FO, Al-Amodi HS, El-Hefnway SM. The Potential Utility of Circulating Oncofetal H19 Derived miR-675 Expression versus Tissue lncRNA-H19 Expression in Diagnosis and Prognosis of HCC in Egyptian Patients. Biomolecules. 2022 12 20; 13(1).
-
Nagalo BM, Zhou Y, Loeuillard EJ, Dumbauld C, Barro O, Elliott NM, Baker AT, Arora M, Bogenberger JM, Meurice N, Petit J, Uson PLS, Aslam F, Raupach E, Gabere M, Basnakian A, Simoes CC, Cannon MJ, Post SR, Buetow K, Chamcheu JC, Barrett MT, Duda DG, Jacobs B, Vile R, Barry MA, Roberts LR, Ilyas S, Borad MJ. Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers. Hepatology. 2023 06 01; 77(6):1943-1957.
-
Ruch B, Wagler J, Kumm K, Zhang C, Katariya NN, Garcia-Saenz-de-Sicilia M, Giorgakis E, Mathur AK. Hepatocellular Carcinoma, Alpha Fetoprotein, and Liver Allocation for Transplantation: Past, Present and Future. Curr Oncol. 2022 10 08; 29(10):7537-7551.
-
Shebl B, Ng D, Lalazar G, Rosemore C, Finkelstein TM, Migler RD, Zheng G, Zhang P, Jiang CS, Qureshi A, Vaughan R, Yarchoan M, de Jong YP, Rice CM, Coffino P, Ortiz MV, Zhou D, Simon SM. Targeting BCL-XL in fibrolamellar hepatocellular carcinoma. JCI Insight. 2022 09 08; 7(17).
-
Thomas CE, Yu YC, Luu HN, Wang R, Paragomi P, Behari J, Yuan JM. Neutrophil-lymphocyte ratio in relation to risk of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. Cancer Med. 2023 02; 12(3):3589-3600.
-
Liu H, Kaltenmeier C, Jonassaint N, Behari J, Duarte-Rojo A, Malik S, Hughes DL, Ganesh S, Reddy D, Powers C, Loseth C, Thompson A, Al Harakeh H, Hill R, Xingyu Z, Diego E, Di Martini A, Bataller R, Molinari M. The closing survival gap after liver transplantation for hepatocellular carcinoma in the United States. HPB (Oxford). 2022 11; 24(11):1994-2005.
-
Kunadirek P, Pinjaroen N, Nookaew I, Tangkijvanich P, Chuaypen N. Transcriptomic Analyses Reveal Long Non-Coding RNA in Peripheral Blood Mononuclear Cells as a Novel Biomarker for Diagnosis and Prognosis of Hepatocellular Carcinoma. Int J Mol Sci. 2022 Jul 17; 23(14).
-
Kalor A, Girometti R, Maheshwari E, Kierans AS, Pugliesi RA, Buros C, Furlan A. Update on MR Contrast Agents for Liver Imaging: What to Use and When. Radiol Clin North Am. 2022 Sep; 60(5):679-694.
-
Boycott C, Beetch M, Yang T, Lubecka K, Ma Y, Zhang J, Kurzava Kendall L, Ullmer M, Ramsey BS, Torregrosa-Allen S, Elzey BD, Cox A, Lanman NA, Hui A, Villanueva N, de Conti A, Huan T, Pogribny I, Stefanska B. Epigenetic aberrations of gene expression in a rat model of hepatocellular carcinoma. Epigenetics. 2022 11; 17(11):1513-1534.
-
Thomas CE, Diergaarde B, Kuipers AL, Adibi JJ, Luu HN, Chang X, Dorajoo R, Heng CK, Khor CC, Wang R, Jin A, Koh WP, Yuan JM. NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian population. Hepatol Commun. 2022 09; 6(9):2310-2321.
-
Song BS, Moon JS, Tian J, Lee HY, Sim BC, Kim SH, Kang SG, Kim JT, Nga HT, Benfeitas R, Kim Y, Park S, Wolfe RR, Eun HS, Shong M, Lee S, Kim IY, Yi HS. Mitoribosomal defects aggravate liver cancer via aberrant glycolytic flux and T cell exhaustion. J Immunother Cancer. 2022 05; 10(5).
-
Perisetti A, Goyal H, Yendala R, Chandan S, Tharian B, Thandassery RB. Sarcopenia in hepatocellular carcinoma: Current knowledge and future directions. World J Gastroenterol. 2022 Jan 28; 28(4):432-448.
-
Smiech M, Leszczynski P, Wardell C, Poznanski P, Pierzchala M, Taniguchi H. Oncogenic Mutation BRAF V600E Changes Phenotypic Behavior of THLE-2 Liver Cells through Alteration of Gene Expression. Int J Mol Sci. 2022 Jan 28; 23(3).
-
Lai JC, Shui AM, Duarte-Rojo A, Ganger DR, Rahimi RS, Huang CY, Yao F, Kappus M, Boyarsky B, McAdams-Demarco M, Volk ML, Dunn MA, Ladner DP, Segev DL, Verna EC, Feng S. Frailty, mortality, and health care utilization after liver transplantation: From the Multicenter Functional Assessment in Liver Transplantation (FrAILT) Study. Hepatology. 2022 06; 75(6):1471-1479.
-
Yu YC, Luu HN, Wang R, Thomas CE, Glynn NW, Youk AO, Behari J, Yuan JM. Serum Biomarkers of Iron Status and Risk of Hepatocellular Carcinoma Development in Patients with Nonalcoholic Fatty Liver Disease. Cancer Epidemiol Biomarkers Prev. 2022 01; 31(1):230-235.
-
Kamel MK, Tuma F, Keane CA, Blebea J. National Trends and Perioperative Outcomes of Robotic-assisted Hepatectomy in the USA: A Propensity-score Matched Analysis from the National Cancer Database. World J Surg. 2022 01; 46(1):189-196.
-
Catania R, Chupetlovska K, Borhani AA, Maheshwari E, Furlan A. Tumor in vein (LR-TIV) and liver imaging reporting and data system (LI-RADS) v2018: diagnostic features, pitfalls, prognostic and management implications. Abdom Radiol (NY). 2021 12; 46(12):5723-5734.
-
Uehara T, Pogribny IP, Rusyn I. The DEN and CCl4 -Induced Mouse Model of Fibrosis and Inflammation-Associated Hepatocellular Carcinoma. Curr Protoc. 2021 Aug; 1(8):e211.
-
Perisetti A, Goyal H, Yendala R, Thandassery RB, Giorgakis E. Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements. World J Gastroenterol. 2021 Jun 28; 27(24):3466-3482.
-
Kunadirek P, Ariyachet C, Sriphoosanaphan S, Pinjaroen N, Sirichindakul P, Nookaew I, Chuaypen N, Tangkijvanich P. Identification of BHLHE40 expression in peripheral blood mononuclear cells as a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma. Sci Rep. 2021 05 27; 11(1):11201.
-
Perisetti A, Kaur R, Thandassery R. Increased Diagnosis of Hepatocellular Carcinoma in Hospitalized Patients with Alcohol Related Hepatitis after the Covid-19 Outbreak: A Global Multi-Center Propensity Matched Analysis. Clin Gastroenterol Hepatol. 2021 11; 19(11):2450-2451.e1.
-
Uson Junior PLS, Nagalo BM, Ahn DH, Bekaii-Saab T, Borad MJ. Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently? Semin Liver Dis. 2021 05; 41(2):136-141.
-
Bajaj G, Sundaram K, Jambhekar K, Ram R. Imaging After Locoregional Therapy for Hepatocellular Carcinoma with Emphasis on LIRADS Treatment Response Assessment Criteria. Semin Ultrasound CT MR. 2021 Aug; 42(4):318-331.
-
Bajaj G, Sundaram K, Jambhekar K, Ram R. Imaging After Locoregional Therapy for Hepatocellular Carcinoma With Emphasis on LIRADS Treatment Response Assessment Criteria. Semin Ultrasound CT MR. 2021 Aug; 42(4):390-404.
-
Sherif ZA, Nouraie SM, Lee E, Aduli F, Brim H, Ashktorab H. Trends in the Incidence of Hepatocellular Carcinoma in Washington DC: A Single Institutional Cohort Study (1959-2013). J Natl Med Assoc. 2021 Aug; 113(4):396-404.
-
Vogl TJ, Riegelbauer LJ, Oppermann E, Kostantin M, Ackermann H, Trzmiel A, Stein S, Eichler K, Zharov VP, Roy D, Schnitzbauer AA, Str?cker B, Pascher A, Bechstein WO, Juratli MA. Early dynamic changes in circulating tumor cells and prognostic relevance following interventional radiological treatments in patients with hepatocellular carcinoma. PLoS One. 2021; 16(2):e0246527.
-
Gordon AC, Gupta AN, Gabr A, Thornburg BG, Kulik LM, Ganger DR, Maddur H, Flamm SL, Boike JR, Moore CM, Borja-Cacho D, Christopher DA, Katariya NN, Ladner DP, Caicedo-Ramirez JC, Riaz A, Salem R, Lewandowski RJ. Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation. J Vasc Interv Radiol. 2021 02; 32(2):211-219.
-
Yuan JM, Wang Y, Wang R, Luu HN, Adams-Haduch J, Koh WP, Gao YT, Behari J, Lotze MT. Serum IL27 in Relation to Risk of Hepatocellular Carcinoma in Two Nested Case-Control Studies. Cancer Epidemiol Biomarkers Prev. 2021 02; 30(2):388-395.
-
Luu HN, Behari J, Goh GB, Wang R, Jin A, Thomas CE, Clemente JC, Odegaard AO, Koh WP, Yuan JM. Composite Score of Healthy Lifestyle Factors and Risk of Hepatocellular Carcinoma: Findings from a Prospective Cohort Study. Cancer Epidemiol Biomarkers Prev. 2021 02; 30(2):380-387.
-
Gabr A, Kulik L, Mouli S, Riaz A, Ali R, Desai K, Mora RA, Ganger D, Maddur H, Flamm S, Boike J, Moore C, Thornburg B, Alasadi A, Baker T, Borja-Cacho D, Katariya N, Ladner DP, Caicedo JC, Lewandowski RJ, Salem R. Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort. Hepatology. 2021 03; 73(3):998-1010.
-
Luu HN, Neelakantan N, Geng TT, Wang R, Goh GB, Clemente JC, Jin A, van Dam RM, Jia W, Behari J, Koh WP, Yuan JM. Quality diet indexes and risk of hepatocellular carcinoma: Findings from the Singapore Chinese Health Study. Int J Cancer. 2021 05 01; 148(9):2102-2114.
-
Hwang S, Park YM, Han KD, Yun JS, Ko SH, Ahn YB, Han JH. Associations of general obesity and central obesity with the risk of hepatocellular carcinoma in a Korean population: A national population-based cohort study. Int J Cancer. 2021 03 01; 148(5):1144-1154.
-
Simoes CC, Thung SN, Fiel MI, Sung MW, Schwartz ME, Ward SC. Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. Mod Pathol. 2021 04; 34(4):823-833.
-
Kim NJ, Rozenberg-Ben-Dror K, Jacob DA, Rich NE, Singal AG, Aby ES, Yang JD, Nguyen V, Pillai A, Fuchs M, Moon AM, Shroff H, Agarwal PD, Perumalswami P, Chandna S, Zhou K, Patel YA, Latt NL, Wong R, Duarte-Rojo A, Lindenmeyer CC, Frenette C, Ge J, Mehta N, Yao F, Benhammou JN, Bloom PP, Leise M, Kim HS, Levy C, Barnard A, Khalili M, Ioannou GN. Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. Clin Gastroenterol Hepatol. 2022 01; 20(1):183-193.
-
de Conti A, Tryndyak V, Heidor R, Jimenez L, Moreno FS, Beland FA, Rusyn I, Pogribny IP. Butyrate-containing structured lipids inhibit RAC1 and epithelial-to-mesenchymal transition markers: a chemopreventive mechanism against hepatocarcinogenesis. J Nutr Biochem. 2020 12; 86:108496.
-
Elsawy H, Algefare AI, Alfwuaires M, Khalil M, Elmenshawy OM, Sedky A, Abdel-Moneim AM. Naringin alleviates methotrexate-induced liver injury in male albino rats and enhances its antitumor efficacy in HepG2 cells. Biosci Rep. 2020 06 26; 40(6).
-
Lew M, Hissong EM, Westerhoff MA, Lamps LW. Optimizing small liver biopsy specimens: a combined cytopathology and surgical pathology perspective. J Am Soc Cytopathol. 2020 Sep - Oct; 9(5):405-421.
-
Salim TI, Nestlerode LC, Lucatorto EL, Wasserman TL, Din HA, Landsittel DP, Tevar AD, Johnson JT, Duarte-Rojo A, Dunn MA. Frailty as Tested by Gait Speed Is a Risk Factor for Liver Transplant Respiratory Complications. Am J Gastroenterol. 2020 06; 115(6):859-866.
-
Thomas CE, Luu HN, Wang R, Adams-Haduch J, Jin A, Koh WP, Yuan JM. Association between Dietary Tomato Intake and the Risk of Hepatocellular Carcinoma: The Singapore Chinese Health Study. Cancer Epidemiol Biomarkers Prev. 2020 07; 29(7):1430-1435.
-
Chen HF, Tilford JM, Schuldt RF, Wan F. Reply to "Risk adjustment in Home Health Care CAHPS". Am J Manag Care. 2020 02; 26(2):59-60.
-
Bhutiani N, O'Brien SJ, Priddy EE, Egger ME, Hong YK, Mercer MK, McMasters KM, Martin RCG, Potts MH, Scoggins CR. Correlating serum alpha-fetoprotein in hepatocellular carcinoma with response to Yttrium-90 transarterial radioembolization with glass microspheres (TheraSphere?). HPB (Oxford). 2020 09; 22(9):1330-1338.
-
Victor DW, Monsour HP, Boktour M, Lunsford K, Balogh J, Graviss EA, Nguyen DT, McFadden R, Divatia MK, Heyne K, Ankoma-Sey V, Egwim C, Galati J, Duchini A, Saharia A, Mobley C, Gaber AO, Ghobrial RM. Outcomes of Liver Transplantation for Hepatocellular Carcinoma Beyond the University of California San Francisco Criteria: A Single-center Experience. Transplantation. 2020 01; 104(1):113-121.
-
Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, Abdelmalek MF, Suzuki A. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology. 2019 10; 70(4):1457-1469.
-
Borowa-Mazgaj B, de Conti A, Tryndyak V, Steward CR, Jimenez L, Melnyk S, Seneshaw M, Mirshahi F, Rusyn I, Beland FA, Sanyal AJ, Pogribny IP. Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis. Toxicol Sci. 2019 08 01; 170(2):273-282.
-
Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019 11; 157(5):1253-1263.e2.
-
Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM, Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette CT, Satapathy SK, Mantry P, Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N, Dhanasekaran R, Odewole M, Kagan S, Marrero JA, Singal AG. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020 04; 18(4):974-983.
-
Arnold CA, Pezhouh MK, Lam-Himlin D, Pittman ME, VandenBussche C, Voltaggio L. 90Y-TheraSpheres: The New Look of Yttrium-90. Am J Surg Pathol. 2019 05; 43(5):688-694.
-
Pedersen KB, Pulliam CF, Patel A, Del Piero F, Watanabe TTN, Wankhade UD, Shankar K, Hicks C, Ronis MJ. Liver tumorigenesis is promoted by a high saturated fat diet specifically in male mice and is associated with hepatic expression of the proto-oncogene Agap2 and enrichment of the intestinal microbiome with Coprococcus. Carcinogenesis. 2019 04 29; 40(2):349-359.
-
Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology. 2019 05; 156(6):1683-1692.e1.
-
Njei B, McCarty TR, Sharma P, Lange A, Najafian N, Ngu JN, Ngomba VE, Echouffo-Tcheugui JB. Bariatric Surgery and Hepatocellular Carcinoma: a Propensity Score-Matched Analysis. Obes Surg. 2018 12; 28(12):3880-3889.
-
Elsayes KM, Kielar AZ, Elmohr MM, Chernyak V, Masch WR, Furlan A, Marks RM, Cruite I, Fowler KJ, Tang A, Bashir MR, Hecht EM, Kamaya A, Jambhekar K, Kamath A, Arora S, Bijan B, Ash R, Kassam Z, Chaudhry H, McGahan JP, Yacoub JH, McInnes M, Fung AW, Shanbhogue K, Lee J, Deshmukh S, Horvat N, Mitchell DG, Do RKG, Surabhi VR, Szklaruk J, Sirlin CB. White paper of the Society of Abdominal Radiology hepatocellular carcinoma diagnosis disease-focused panel on LI-RADS v2018 for CT and MRI. Abdom Radiol (NY). 2018 10; 43(10):2625-2642.
-
Jamshidi-Parsian A, Griffin RJ, Kore RA, Todorova VK, Makhoul I. Tumor-endothelial cell interaction in an experimental model of human hepatocellular carcinoma. Exp Cell Res. 2018 11 01; 372(1):16-24.
-
DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, Bekaii-Saab TS, Borad MJ. Novel immunotherapy strategies for hepatobiliary cancers. Immunotherapy. 2018 09; 10(12):1077-1091.
-
Dechassa ML, Tryndyak V, de Conti A, Xiao W, Beland FA, Pogribny IP. Identification of chromatin-accessible domains in non-alcoholic steatohepatitis-derived hepatocellular carcinoma. Mol Carcinog. 2018 08; 57(8):978-987.
-
Pogribny IP, Dreval K, Kindrat I, Melnyk S, Jimenez L, de Conti A, Tryndyak V, Pogribna M, Ortega JF, James SJ, Rusyn I, Beland FA. Epigenetically mediated inhibition of S-adenosylhomocysteine hydrolase and the associated dysregulation of 1-carbon metabolism in nonalcoholic steatohepatitis and hepatocellular carcinoma. FASEB J. 2018 03; 32(3):1591-1601.
-
Orcutt ST, Anaya DA. Liver Resection and Surgical Strategies for Management of Primary Liver Cancer. Cancer Control. 2018 Jan-Mar; 25(1):1073274817744621.
-
Sade R, Kantarci M, Ogul H, Gundogdu B, Aydinli B. Differentiation between hepatic alveolar echinococcosis and primary hepatic malignancy with diffusion-weighted magnetic resonance imaging. Diagn Interv Imaging. 2018 Mar; 99(3):169-177.
-
Patt YZ, Murad W, Fekrazad MH, Baron AD, Bansal P, Boumber Y, Steinberg K, Lee SJ, Bedrick E, Du R, Lee FC. INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial. Cancer Med. 2017 Sep; 6(9):2042-2051.
-
George NE, Raghavapuram S, Banerjee D, Al-Shoha M, Fedda F, Tharian B. Ectopic Hepatocellular Carcinoma within a Choledochal Cyst Diagnosed Using Single-Operator Digital Cholangioscopy. Am J Gastroenterol. 2017 Aug; 112(8):1347-1348.
-
Thandassery RB, Kaabi SA, Soofi ME, Tharian B, Singh R. Noninvasive serum models to predict significant liver related events in chronic hepatitis C. Hepatol Int. 2017 Jul; 11(4):401-408.
-
de Conti A, Dreval K, Tryndyak V, Orisakwe OE, Ross SA, Beland FA, Pogribny IP. Inhibition of the Cell Death Pathway in Nonalcoholic Steatohepatitis (NASH)-Related Hepatocarcinogenesis Is Associated with Histone H4 lysine 16 Deacetylation. Mol Cancer Res. 2017 09; 15(9):1163-1172.
-
Moustafa AS, Abdel Aal AK, Ertel N, Saad N, DuBay D, Saddekni S. Chemoembolization of Hepatocellular Carcinoma with Extrahepatic Collateral Blood Supply: Anatomic and Technical Considerations. Radiographics. 2017 May-Jun; 37(3):963-977.
-
Furuta M, Ueno M, Fujimoto A, Hayami S, Yasukawa S, Kojima F, Arihiro K, Kawakami Y, Wardell CP, Shiraishi Y, Tanaka H, Nakano K, Maejima K, Sasaki-Oku A, Tokunaga N, Boroevich KA, Abe T, Aikata H, Ohdan H, Gotoh K, Kubo M, Tsunoda T, Miyano S, Chayama K, Yamaue H, Nakagawa H. Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors. J Hepatol. 2017 02; 66(2):363-373.
-
Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2016 11; 44(10):1090-1101.
-
Moreno FS, Heidor R, Pogribny IP. Nutritional Epigenetics and the Prevention of Hepatocellular Carcinoma with Bioactive Food Constituents. Nutr Cancer. 2016 07; 68(5):719-33.
-
Ortega JF, de Conti A, Tryndyak V, Furtado KS, Heidor R, Horst MA, Fernandes LH, Tavares PE, Pogribna M, Shpyleva S, Beland FA, Pogribny IP, Moreno FS. Suppressing activity of tributyrin on hepatocarcinogenesis is associated with inhibiting the p53-CRM1 interaction and changing the cellular compartmentalization of p53 protein. Oncotarget. 2016 Apr 26; 7(17):24339-47.
-
Mercer KE, Pulliam C, Hennings L, Lai K, Cleves M, Jones E, Drake RR, Ronis M. Soy Protein Isolate Protects Against Ethanol-Mediated Tumor Progression in Diethylnitrosamine-Treated Male Mice. Cancer Prev Res (Phila). 2016 06; 9(6):466-75.
-
Chappell G, Silva GO, Uehara T, Pogribny IP, Rusyn I. Characterization of copy number alterations in a mouse model of fibrosis-associated hepatocellular carcinoma reveals concordance with human disease. Cancer Med. 2016 Mar; 5(3):574-85.
-
Kindrat I, Tryndyak V, de Conti A, Shpyleva S, Mudalige TK, Kobets T, Erstenyuk AM, Beland FA, Pogribny IP. MicroRNA-152-mediated dysregulation of hepatic transferrin receptor 1 in liver carcinogenesis. Oncotarget. 2016 Jan 12; 7(2):1276-87.
-
Orcutt ST, Sultenfuss MA, Anaya DA. A Large Liver Mass With Acute Hemorrhage. JAMA Surg. 2016 Jan; 151(1):83-4.
-
Zaller ND, Patry EJ, Bazerman LB, Noska A, Kuo I, Kurth A, Beckwith CG. A Pilot Study of Rapid Hepatitis C Testing in Probation and Parole Populations in Rhode Island. J Health Care Poor Underserved. 2016; 27(2A):214-23.
-
Yu D, Green B, Marrone A, Guo Y, Kadlubar S, Lin D, Fuscoe J, Pogribny I, Ning B. Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma. Sci Rep. 2015 Feb 23; 5:8534.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|